Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8955905 | Maturitas | 2018 | 23 Pages |
Abstract
Metabolic changes during the menopausal transition include an increase in and the central redistribution of adipose tissue, as well as a decrease in energy expenditure. In addition, there is impairment of insulin secretion and insulin sensitivity and an increase in the risk of T2DM. MHT has a favourable effect on glucose metabolism, both in women with and in women without T2DM, while it may delay the onset of T2DM. MHT in women with T2DM should be administered according to their risk of cardiovascular disease (CVD). In women with T2DM and low CVD risk, oral oestrogens may be preferred, while transdermal 17β-oestradiol is preferred for women with T2DM and coexistent CVD risk factors, such as obesity. In any case, a progestogen with neutral effects on glucose metabolism should be used, such as progesterone, dydrogesterone or transdermal norethisterone. Postmenopausal women with T2DM should be managed primarily with lifestyle intervention, including diet and exercise. Most of them will eventually require pharmacological therapy. The selection of antidiabetic medications should be based on the patient's specific characteristics and comorbidities, as well on the metabolic, cardiovascular and bone effects of the medications.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Radoslaw Slopien, Ewa Wender-Ozegowska, Anita Rogowicz-Frontczak, Blazej Meczekalski, Dorota Zozulinska-Ziolkiewicz, Jesse D. Jaremek, Antonio Cano, Peter Chedraui, Dimitrios G. Goulis, Patrice Lopes, Gita Mishra, Alfred Mueck, Margaret Rees,